Belinostat

Generic Name
Belinostat
Brand Names
Beleodaq
Drug Type
Small Molecule
Chemical Formula
C15H14N2O4S
CAS Number
866323-14-0
Unique Ingredient Identifier
F4H96P17NZ
Background

Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for th...

Indication

Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline thrombocytopenia .

Associated Conditions
Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
Associated Therapies
-
Clinical Trials
Related News

MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

First Posted Date
2014-05-14
Last Posted Date
2023-05-06
Lead Sponsor
Emory University
Target Recruit Count
29
Registration Number
NCT02137759
Locations
🇺🇸

Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Phase 1
Completed
Conditions
Peripheral T-cell Lymphoma
Interventions
Drug: Belinostat
Drug: CHOP
First Posted Date
2013-04-24
Last Posted Date
2020-01-03
Lead Sponsor
Acrotech Biopharma Inc.
Target Recruit Count
23
Registration Number
NCT01839097
Locations
🇺🇸

Hematology - Oncology Associates of Northern NJ P.A, Morristown, New Jersey, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 5 locations

Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL

First Posted Date
2012-09-17
Last Posted Date
2018-08-28
Lead Sponsor
University of Arizona
Target Recruit Count
5
Registration Number
NCT01686165
Locations
🇺🇸

University of Arizona Cancer Center, Tucson, Arizona, United States

Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer

Phase 1
Completed
Conditions
Advanced Cancer
Interventions
Drug: Belinostat
First Posted Date
2012-04-24
Last Posted Date
2020-01-03
Lead Sponsor
Acrotech Biopharma Inc.
Target Recruit Count
6
Registration Number
NCT01583777
Locations
🇪🇸

Hospital Universitario Madrid Sanchinarro, Madrid, Spain

Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction

Phase 1
Completed
Conditions
Lymphomas
Neoplasms
Interventions
Drug: Belinostat
First Posted Date
2011-01-10
Last Posted Date
2019-03-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
72
Registration Number
NCT01273155
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

🇺🇸

USC Norris Cancer Center, Los Angeles, California, United States

🇺🇸

University of California, Davis, Davis, California, United States

and more 4 locations

Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome

First Posted Date
2010-02-25
Last Posted Date
2016-04-15
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
41
Registration Number
NCT01075425
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

First Posted Date
2009-10-12
Last Posted Date
2019-07-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
29
Registration Number
NCT00993616
Locations
🇺🇸

Green Bay Oncology - Oconto Falls, Oconto Falls, Wisconsin, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Women's Cancer Center of Nevada, Las Vegas, Nevada, United States

and more 78 locations

A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers

First Posted Date
2009-06-23
Last Posted Date
2018-10-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
28
Registration Number
NCT00926640
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

Phase 2
Completed
Conditions
Peripheral T-cell Lymphoma
Interventions
Drug: Belinostat
First Posted Date
2009-03-20
Last Posted Date
2021-10-29
Lead Sponsor
Spectrum Pharmaceuticals, Inc
Target Recruit Count
129
Registration Number
NCT00865969
Locations
🇺🇸

New York University, New York, New York, United States

🇺🇸

Upstate Medical Univeristy Syracuse, Syracuse, New York, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

and more 114 locations

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

First Posted Date
2007-01-15
Last Posted Date
2015-07-28
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
80
Registration Number
NCT00421889
Locations
🇺🇸

Greater Baltimore Medical Center, Baltimore, Maryland, United States

🇺🇸

Hematology & Oncology Specialists, LLC, Metairie, Louisiana, United States

🇬🇧

The Royal Marsden NHS Trust, Surrey, United Kingdom

and more 8 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy